How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity?
Valérie Janelle, Alain Lamarre

To cite this version:
How informative is the immune response against surrogate tumor antigens to assess antitumor immunity?

Valérie Janelle1,2 and Alain Lamarre1,2 *

1 Immunovirology Laboratory, Institut National de la Recherche Scientifique, INRS-Institut Armand-Frappier, Laval, QC, Canada
2 Department of Biology, Biomed Research Center, Université du Québec à Montréal, Montréal, QC, Canada
*Correspondence: alain.lamarre@iaf.inrs.ca

Edited by:
Philippe Fournier, German Cancer Research Center (DKFZ), Germany

Reviewed by:
Volker Schirrmacher, German Cancer Research Center (DKFZ), Germany
John Cameron Bell, Ottawa Hospital Research Institute, Canada

Keywords: oncolytic viruses, tumor antigens, CD8-positive T lymphocytes, B16F10, VSV

A commentary on

The strength of the T cell response against a surrogate tumor antigen (TA) induced by oncolytic vesicular stomatitis virus (VSV) therapy does not correlate with tumor control by Janelle V, Langlois M-P, Lapierre P, Charpentier T, Poliquin L, Lamarre A. Mol Ther (2014). doi: 10.1038/mt.2014.34

The last decade has seen the development of numerous oncolytic vesicular stomatitis virus (VSV) therapy for tumor control. Using oncolytic viruses against cancer has grown tremendously and a number of promising candidates are now in preclinical and clinical studies. Tumor regression in vivo following viral infection has been shown to be a multifactorial process (1). The reductionist view of viruses simply causing direct lysis of infected cancer cells has now been replaced by a view including the complex interplay between viruses and the tumor environment. The important role of the immune response in either limiting or enhancing OV therapy is also now well recognized (2, 3). The prototypic Rhabdoviridae VSV has generated encouraging results in various experimental tumor models and is now used in a phase I clinical trial in patients with liver cancer (www.clinicaltrials.gov; #NCT01628640). VSV possesses intrinsic oncolytic properties as it replicates more efficiently in type-I interferon (IFN)-defective cells, a pathway frequently impaired during tumorigenesis (4). Cancer therapy using VSV has been shown to generate a variety of immune responses including tumor-specific CD8+ T cells that are induced following the release of TA by infected cells (5). However, the tumor-specific immune response generated following VSV treatment is usually weak and often only leads to transient tumor control. Experimental tumor models expressing various surrogate non-self-TA have been developed over the years to more easily assess the magnitude and quality of immune responses generated against tumors. However, whether these responses are always representative of physiological antitumor immune responses is unclear.

Recently, our group characterized various VSV glycoprotein (G) mutants capable of interfering with host cell metabolism by inhibiting cellular transcription and translation in a kinetic similar to WT VSV as opposed to the prototypic matrix (M) mutant (M51R) that is slightly attenuated in vitro (6). Furthermore, VSV G mutant-treated mice proved to be more cytolytic for B16 melanoma cells in vitro than the M mutant. To analyze their oncolytic potential in vivo, we used an immunocompetent mouse model implanted with B16 tumors transfected with a DNA minigene encoding the immunodominant CD8+ T cell epitope of the lymphocytic choriomeningitis virus (glycoprotein aa 33–41) (7) as a surrogate non-self-TA (B16gp33) (8). Mice were injected subcutaneously into the flank with B16gp33 cells and when tumors reached a palpable size (day 7), animals were treated intratumorally every second day with three doses (days 7, 9, and 11) of WT VSV or the G or M mutants. Tetramer and intracellular cytokine staining analysis revealed that CD8+ T cells harvested from mice treated with WT VSV or the G mutants developed a polyfunctional gp33-specific immune response. Surprisingly, however, the strength of the gp33-specific immune response generated did not correlate with the ability of a particular strain of VSV to slow down parental B16 growth and improve mice survival. Treatment with WT VSV was the poorest at controlling B16 tumor progression even though it induced a strong CTL response against gp33. On the other hand, M51R was more efficient than WT VSV at slowing down B16 growth despite the fact that this virus induced the lowest gp33-specific T cell response. We therefore determined whether CD8+ T cell responses directed against endogenous self-TA were involved in limiting tumor progression. CTL responses against self-TA, such as TRP-1 and gp100, were barely detectable ex vivo when analyzed separately. However, adoptive transfer of purified CD8+ T cells harvested from M51R-treated B16gp33 melanoma-bearing mice into naive mice provided better protection against parental B16 tumor implantation compared to CTLs taken from WT or G mutant-treated mice. These results suggest that the M mutant, despite being the weakest at inducing a T cell response against the surrogate non-self-TA gp33, induces the broadest antitumoral CTL response.

B16 melanoma is a highly aggressive tumor model in part because major histocompatibility complex class I (MHC-I) surface expression is very low on these...
cells. Strikingly, B16 infection with VSV M mutant induced the upregulation of surface MHC-I both in vitro and in vivo, a phenomenon that was not observed for WT VSV of the G mutants (8). The matrix protein of VSV was previously shown to alter trafficking of a molecule structurally similar to MHC-I, namely CD1d (9, 10). This leads to inhibition of antigen presentation to natural killer T (NKT) cells (11). Thus, VSV matrix protein could participate in the retention of MHC-I molecules within infected cells while the mutated protein in M51R may lack this ability. Thus, surface MHC-I upregulation following M51R treatment likely explains the significantly improved CD8+ T cell-dependent survival despite the poor gp33-specific CTL response induced by this mutant. This may subsequently lead to presentation of a broader pool of tumor-associated antigens that may be taken-up by antigen-presenting cells such as dendritic cells and lead to T lymphocyte activation. Infection with WT VSV or glycoprotein (G) mutants induces a strong CD8+ cytotoxic T lymphocyte (CTL) response against a surrogate non-self antigen (gp33) correlating with their ability to limit tumor growth (left panel). In contrast, the matrix mutant of VSV (M51R), although inefficient at inducing gp33-specific CTLs, is highly effective at slowing down tumor progression, likely through its capacity to induce the upregulation of MHC-I surface expression on cancer cells allowing for the induction of a broader CTL response (right panel). CTLs, cytotoxic T lymphocytes; DC, dendritic cells; MDSC, myeloid-derived suppressor cell; MHC-I, major histocompatibility complex class I; NK, natural killer; VSV, vesicular stomatitis virus.

FIGURE 1 | Induction of a functional tumor-specific immune response is achieved through diverse mechanisms for different VSV strains: proposed model. VSV is quickly cleared from tumor tissue by the rapid induction of innate antiviral defense mechanisms and neutralizing antibodies. Nonetheless, the proinflammatory milieu generated in response to infection promotes leukocyte infiltration. Infection can result in tumor cell lysis either directly as a result of virus replication or indirectly through the action of innate immune cells generating a pool of tumor-associated antigens that may be taken-up by antigen-presenting cells such as dendritic cells and lead to T lymphocyte activation. Infection with WT VSV or glycoprotein (G) mutants

REFERENCES

4. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune

ACKNOWLEDGMENTS

This work was supported by the Canadian Institutes of Health Research and by the J.-Louis Lévesque Foundation.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 13 March 2014; accepted: 21 May 2014; published online: 04 June 2014.


This article was submitted to Tumor Immunity, a section of the journal Frontiers in Oncology.

Copyright © 2014 Janelle and Lamarre. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.